Exhibit 99.1  Gemini Therapeutics Provides GEM103 Program Update

CAMBRIDGE, Mass. - January** **10, 2022** - Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103's clinical development program.

This is the opening of the release as filed. Read the full document on SEC.gov, or read it in full on SPAC Watch with the trust, deadline and warrant terms alongside it.